Trial Profile
Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers. U19-HIPC Vaccination and Infection: Indicators of Immunological Health and Responsiveness
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 15 May 2017
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; MEDI 3250 (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Acronyms SLVP032
- 20 Jan 2017 New trial record